Gsk (GSK) Intangibles (2009 - 2026)

Gsk (GSK) has 18 years of Intangibles data on file, last reported at $22.5 billion in Q2 2026.

• For the quarter ending Q2 2026, Intangibles rose 9.9% year-over-year to $22.5 billion; the trailing twelve-month figure through Jun 2026 stood at $22.5 billion (up 9.9% YoY), and the FY2025 full-year result was $22.3 billion, up 12.33% from the prior year.
• Intangibles was $22.5 billion for Q2 2026 at Gsk, down from $24.5 billion in the prior quarter.
• In the past five years, Intangibles ranged from a high of $26.0 billion in Q1 2022 to a low of $14.3 billion in Q2 2022.
• A 5-year average of $20.1 billion and a median of $19.7 billion in 2024 frame the typical range for Intangibles.
• Across the five-year window, Intangibles plunged 65.07% in 2022 and soared 35.72% in 2023, its largest moves.
• Gsk's Intangibles stood at $16.8 billion in 2022, then increased by 9.14% to $18.3 billion in 2023, then climbed by 8.64% to $19.9 billion in 2024, then climbed by 11.87% to $22.3 billion in 2025, then grew by 1.19% to $22.5 billion in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $22.5 billion in Q2 2026, $24.5 billion in Q1 2026, and $22.3 billion in Q4 2025.